哺乳類細胞株開発の世界市場（2026年～2032年）

• 英文タイトル：Global Mammalian Cell Line Development Market Growth (Status and Outlook) 2026-2032

• レポートコード：MRC8822MH60092 • 出版社/出版日：LP Information / 2026年3月 • レポート形態：英語、PDF、130ページ • 納品方法：Eメール（納期：3日） • 産業分類：バイオ

• 販売価格（消費税別）

Single User	￥570,960 (USD3,660)	▷ お問い合わせ
Multi User	￥856,440 (USD5,490)	▷ お問い合わせ
Corporate User	￥1,141,920 (USD7,320)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

世界の哺乳類細胞株開発市場規模は、2025年の2億7,200万米ドルから2032年には5億1,900万米ドルへと拡大すると予測されており、2026年から2032年にかけて年平均成長率（CAGR）9.9％で成長すると見込まれています。 哺乳類細胞株の開発とは、研究、バイオ医薬品の製造、およびその他の用途に利用するため、ヒト、マウス、サルなどの哺乳類由来の細胞株を作成・最適化するプロセスを指します。これには、適切な細胞タイプの選定、安定した細胞株の樹立、そして高い生産性と一貫性を確保するための培養条件の最適化が含まれます。哺乳類細胞株は、ヒト細胞の生理機能に極めて近い特性を持つため、組換えタンパク質、モノクローナル抗体、ワクチンの製造に広く利用されており、疾患メカニズムの解明や新規治療法の開発において貴重なツールとなっています。哺乳類細胞株の開発は、バイオテクノロジーおよび生物医学研究における重要なステップであり、複雑な生体分子の生産を可能にし、人間の健康と疾患に関する理解を深めることに寄与しています。 哺乳類細胞株開発業界は、技術革新、規制要件、そして新たな治療パラダイムに牽引され、変革的な進歩を遂げつつあります。中心的なトレンドの一つは、CRISPR-Cas9遺伝子編集技術の急速な普及です。この技術は、タンパク質発現、代謝経路、および宿主細胞の耐性を高めるための精密なゲノム改変を可能にし、細胞株の最適化に革命をもたらしました。また、単一細胞シーケンシング（scRNA-seq）とAIを活用した解析技術が、細胞株の特性評価とプロセス最適化のあり方を一新しています。scRNA-seqは数千個の個々の細胞をプロファイリングすることで、希少な高産生クローンを特定し、細胞集団内の不均一性を明らかにする一方、AIアルゴリズムはクローンの安定性を予測し、培養条件を最適化する。例えば、マルチオミクスデータで学習させたAIモデルは、遺伝的および表現型のプロファイルが良好なクローンを優先的に選定することで、クローンスクリーニング時間を40％短縮できる。 柔軟性とコスト効率へのニーズを背景に、連続製造およびシングルユース技術も普及しつつあります。シングルユースバイオリアクターや統合型ダウンストリーム処理システム（クロマトグラフィーカラムなど）は、洗浄バリデーション工程を不要にし、設備投資コストを削減します。一方、連続灌流培養は高い細胞密度（5,000万細胞/mL以上）を維持し、生産サイクルを延長することで、体積あたりの生産性を2～3倍に高めます。 規制上の圧力により、品質管理とトレーサビリティの強化が求められている。FDAが2023年に治療製品局（OTP）を設立したことで、細胞・遺伝子治療の審査が効率化され、リアルタイムモニタリングや長期安全性データ（例：CAR-T患者に対する15年間の追跡調査）が重視されるようになった。一方、中国やインドなどの新興市場が成長を牽引しており、中国は幹細胞研究に5,800万ドルを投資し、インドの細胞株開発市場は2030年まで年平均成長率（CAGR）11.6%で拡大すると予測されています。これらの地域は、コスト効率の高い製造体制と政府の支援策を活用し、バイオシミラーや新規生物製剤の世界的な拠点となることを目指しています。 汚染リスク（例：細胞培養の5～30％に影響を与えるマイコプラズマ）や高い開発コスト（例：CHO細胞1バイアルのコストは約4,250ドル）など、課題は依然として残っている。しかし、自動画像解析システムやCRISPRベースの汚染検出ツールの進歩により、これらの問題は緩和されつつある。 LPI（LP Information）の最新調査レポート『哺乳類細胞株開発産業予測』は、過去の売上実績を検証し、2025年の世界の哺乳類細胞株開発総売上高を分析するとともに、2026年から2032年までの予測売上高について、地域および市場セクター別の包括的な分析を提供しています。本レポートでは、哺乳類細胞株開発の売上高を地域、市場セクター、サブセクター別に分類し、世界の哺乳類細胞株開発業界について、単位：百万米ドルで詳細な分析を提供しています。 本インサイトレポートは、世界の哺乳類細胞株開発の全体像を包括的に分析し、製品セグメンテーション、企業設立、収益、市場シェア、最新動向、M&A活動に関連する主要なトレンドを明らかにしています。また、本レポートでは、哺乳類細胞株開発のポートフォリオと能力、市場参入戦略、市場での位置づけ、および地理的展開に焦点を当て、主要グローバル企業の戦略を分析し、加速する世界の哺乳類細胞株開発市場における各企業の独自の立場をより深く理解できるようにしています。 本インサイトレポートは、哺乳類細胞株開発の世界的な見通しを形作る主要な市場動向、推進要因、および影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化することで、新たな機会の領域を浮き彫りにします。数百件に及ぶボトムアップ型の定性的・定量的市場データに基づく透明性の高い方法論を用いることで、本調査の予測は、世界の哺乳類細胞株開発の現状と将来の軌跡について、極めて精緻な見解を提供します。 本レポートは、製品タイプ、用途、主要企業、主要地域および国別に、哺乳類細胞株開発市場の包括的な概要、市場シェア、および成長機会を提示しています。 タイプ別セグメンテーション： CHO（チャイニーズハムスター卵巣）細胞 HEK（ヒト胚腎）細胞 NS0（マウス骨髄腫）細胞 BHK（ベビーハムスター腎）細胞 その他 用途別セグメンテーション： バイオ医薬品製造 創薬および開発 毒性試験 その他 本レポートでは、地域別にも市場を分類しています： 南北アメリカ 米国 カナダ メキシコ ブラジル アジア太平洋地域（APAC） 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下に紹介する企業は、主要な専門家からの情報および各社の事業範囲、製品ポートフォリオ、市場浸透度を分析した上で選定されています。 Thermo Fisher Scientific AGC Biologics FyoniBio KBI Biopharma Hera Biolabs Catalent Bionova Lonza Creative Biolabs Fraunhofer Cytena GTP Bioways Abzena FUJIFILM Diosynth Biotechnologies WuXi Biologics Northway Biotech Sartorius EirGenix Tanvex Menarini Biotech Creative Biogene Rodon Biologics

The global Mammalian Cell Line Development market size is predicted to grow from US$ 272 million in 2025 to US$ 519 million in 2032; it is expected to grow at a CAGR of 9.9% from 2026 to 2032.

Mammalian cell line development refers to the process of creating and optimizing cell lines derived from mammalian species, such as humans, mice, or monkeys, for use in research, biopharmaceutical production, and other applications. This involves selecting a suitable cell type, establishing a stable cell line, and optimizing growth conditions to ensure high productivity and consistency. Mammalian cell lines are commonly used in the production of recombinant proteins, monoclonal antibodies, and vaccines, as they closely mimic the physiology and function of human cells, making them valuable tools for studying disease mechanisms and developing new therapies. The development of mammalian cell lines is a crucial step in biotechnology and biomedical research, enabling the production of complex biological molecules and advancing our understanding of human health and disease.

The mammalian cell line development industry is undergoing transformative advancements driven by technological innovation, regulatory demands, and emerging therapeutic paradigms. A central trend is the accelerated adoption of CRISPR-Cas9 gene-editing technologies, which have revolutionized cell line optimization by enabling precise genomic modifications to enhance protein expression, metabolic pathways, and host cell resilience. Single-cell sequencing (scRNA-seq) and AI-driven analytics are reshaping cell line characterization and process optimization. By profiling thousands of individual cells, scRNA-seq identifies rare high-producing clones and uncovers heterogeneity in cell populations, while AI algorithms predict clone stability and optimize culture conditions. For example, AI models trained on multi-omics data can reduce clone screening time by 40% by prioritizing clones with favorable genetic and phenotypic profiles.
Continuous manufacturing and single-use technologies are also gaining traction, driven by the need for flexibility and cost efficiency. Single-use bioreactors and integrated downstream processing systems (e.g., chromatography columns) eliminate cleaning validation steps and reduce capital costs, while continuous perfusion cultures maintain high cell densities (>50 million cells/mL) and prolong production cycles, increasing volumetric productivity by 2–3 fold.
Regulatory pressures are pushing for enhanced quality control and traceability. The FDA’s 2023 establishment of the Office of Therapeutic Products (OTP) streamlines reviews for cell and gene therapies, emphasizing real-time monitoring and long-term safety data (e.g., 15-year follow-up for CAR-T patients). Meanwhile, emerging markets like China and India are driving growth, with China investing $58 million in stem cell research and India’s cell line development market projected to grow at 11.6% CAGR through 2030. These regions are leveraging cost-effective manufacturing and government incentives to become global hubs for biosimilars and novel biologics.
Challenges persist, including contamination risks (e.g., mycoplasma affecting 5–30% of cell cultures) and high development costs (e.g., a vial of CHO cells costs ~$4,250). However, advancements in automated imaging systems and CRISPR-based contamination detection tools are mitigating these issues.

LPI (LP Information)’ newest research report, the “Mammalian Cell Line Development Industry Forecast” looks at past sales and reviews total world Mammalian Cell Line Development sales in 2025, providing a comprehensive analysis by region and market sector of projected Mammalian Cell Line Development sales for 2026 through 2032. With Mammalian Cell Line Development sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mammalian Cell Line Development industry.

This Insight Report provides a comprehensive analysis of the global Mammalian Cell Line Development landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Mammalian Cell Line Development portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mammalian Cell Line Development market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mammalian Cell Line Development and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mammalian Cell Line Development.

This report presents a comprehensive overview, market shares, and growth opportunities of Mammalian Cell Line Development market by product type, application, key players and key regions and countries.

Segmentation by Type:
CHO (Chinese Hamster Ovary) Cells
HEK (Human Embryonic Kidney) Cells
NS0 (Mouse Myeloma) Cells
BHK (Baby Hamster Kidney) Cells
Others

Segmentation by Application:
Biopharmaceutical Production
Drug Discovery and Development
Toxicity Testing
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.

Thermo Fisher Scientific
AGC Biologics
FyoniBio
KBI Biopharma
Hera Biolabs
Catalent
Bionova
Lonza
Creative Biolabs
Fraunhofer
Cytena
GTP Bioways
Abzena
FUJIFILM Diosynth Biotechnologies
WuXi Biologics
Northway Biotech
Sartorius
EirGenix
Tanvex
Menarini Biotech
Creative Biogene
Rodon Biologics

レポート目次

---

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Mammalian Cell Line Development Market Size (2021-2032)
2.1.2 Mammalian Cell Line Development Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Mammalian Cell Line Development by Country/Region (2021, 2025 & 2032)
2.2 Mammalian Cell Line Development Segment by Type
2.2.1 CHO (Chinese Hamster Ovary) Cells
2.2.2 HEK (Human Embryonic Kidney) Cells
2.2.3 NS0 (Mouse Myeloma) Cells
2.2.4 BHK (Baby Hamster Kidney) Cells
2.2.5 Others
2.2.6 Mammalian Cell Line Development Market Size by Type
2.2.6.1 Mammalian Cell Line Development Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Mammalian Cell Line Development Market Size Market Share by Type (2021-2026)
2.3 Mammalian Cell Line Development Segment by Application
2.3.1 Biopharmaceutical Production
2.3.2 Drug Discovery and Development
2.3.3 Toxicity Testing
2.3.4 Others
2.3.5 Mammalian Cell Line Development Market Size by Application
2.3.5.1 Mammalian Cell Line Development Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Mammalian Cell Line Development Market Size Market Share by Application (2021-2026)
3 Mammalian Cell Line Development Market Size by Player
3.1 Mammalian Cell Line Development Market Size Market Share by Player
3.1.1 Global Mammalian Cell Line Development Revenue by Player (2021-2026)
3.1.2 Global Mammalian Cell Line Development Revenue Market Share by Player (2021-2026)
3.2 Global Mammalian Cell Line Development Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Mammalian Cell Line Development by Region
4.1 Mammalian Cell Line Development Market Size by Region (2021-2026)
4.2 Global Mammalian Cell Line Development Annual Revenue by Country/Region (2021-2026)
4.3 Americas Mammalian Cell Line Development Market Size Growth (2021-2026)
4.4 APAC Mammalian Cell Line Development Market Size Growth (2021-2026)
4.5 Europe Mammalian Cell Line Development Market Size Growth (2021-2026)
4.6 Middle East & Africa Mammalian Cell Line Development Market Size Growth (2021-2026)
5 Americas
5.1 Americas Mammalian Cell Line Development Market Size by Country (2021-2026)
5.2 Americas Mammalian Cell Line Development Market Size by Type (2021-2026)
5.3 Americas Mammalian Cell Line Development Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Mammalian Cell Line Development Market Size by Region (2021-2026)
6.2 APAC Mammalian Cell Line Development Market Size by Type (2021-2026)
6.3 APAC Mammalian Cell Line Development Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Mammalian Cell Line Development Market Size by Country (2021-2026)
7.2 Europe Mammalian Cell Line Development Market Size by Type (2021-2026)
7.3 Europe Mammalian Cell Line Development Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Mammalian Cell Line Development by Region (2021-2026)
8.2 Middle East & Africa Mammalian Cell Line Development Market Size by Type (2021-2026)
8.3 Middle East & Africa Mammalian Cell Line Development Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Mammalian Cell Line Development Market Forecast
10.1 Global Mammalian Cell Line Development Forecast by Region (2027-2032)
10.1.1 Global Mammalian Cell Line Development Forecast by Region (2027-2032)
10.1.2 Americas Mammalian Cell Line Development Forecast
10.1.3 APAC Mammalian Cell Line Development Forecast
10.1.4 Europe Mammalian Cell Line Development Forecast
10.1.5 Middle East & Africa Mammalian Cell Line Development Forecast
10.2 Americas Mammalian Cell Line Development Forecast by Country (2027-2032)
10.2.1 United States Market Mammalian Cell Line Development Forecast
10.2.2 Canada Market Mammalian Cell Line Development Forecast
10.2.3 Mexico Market Mammalian Cell Line Development Forecast
10.2.4 Brazil Market Mammalian Cell Line Development Forecast
10.3 APAC Mammalian Cell Line Development Forecast by Region (2027-2032)
10.3.1 China Mammalian Cell Line Development Market Forecast
10.3.2 Japan Market Mammalian Cell Line Development Forecast
10.3.3 Korea Market Mammalian Cell Line Development Forecast
10.3.4 Southeast Asia Market Mammalian Cell Line Development Forecast
10.3.5 India Market Mammalian Cell Line Development Forecast
10.3.6 Australia Market Mammalian Cell Line Development Forecast
10.4 Europe Mammalian Cell Line Development Forecast by Country (2027-2032)
10.4.1 Germany Market Mammalian Cell Line Development Forecast
10.4.2 France Market Mammalian Cell Line Development Forecast
10.4.3 UK Market Mammalian Cell Line Development Forecast
10.4.4 Italy Market Mammalian Cell Line Development Forecast
10.4.5 Russia Market Mammalian Cell Line Development Forecast
10.5 Middle East & Africa Mammalian Cell Line Development Forecast by Region (2027-2032)
10.5.1 Egypt Market Mammalian Cell Line Development Forecast
10.5.2 South Africa Market Mammalian Cell Line Development Forecast
10.5.3 Israel Market Mammalian Cell Line Development Forecast
10.5.4 Turkey Market Mammalian Cell Line Development Forecast
10.6 Global Mammalian Cell Line Development Forecast by Type (2027-2032)
10.7 Global Mammalian Cell Line Development Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Mammalian Cell Line Development Forecast
11 Key Players Analysis
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Information
11.1.2 Thermo Fisher Scientific Mammalian Cell Line Development Product Offered
11.1.3 Thermo Fisher Scientific Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Thermo Fisher Scientific Main Business Overview
11.1.5 Thermo Fisher Scientific Latest Developments
11.2 AGC Biologics
11.2.1 AGC Biologics Company Information
11.2.2 AGC Biologics Mammalian Cell Line Development Product Offered
11.2.3 AGC Biologics Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 AGC Biologics Main Business Overview
11.2.5 AGC Biologics Latest Developments
11.3 FyoniBio
11.3.1 FyoniBio Company Information
11.3.2 FyoniBio Mammalian Cell Line Development Product Offered
11.3.3 FyoniBio Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 FyoniBio Main Business Overview
11.3.5 FyoniBio Latest Developments
11.4 KBI Biopharma
11.4.1 KBI Biopharma Company Information
11.4.2 KBI Biopharma Mammalian Cell Line Development Product Offered
11.4.3 KBI Biopharma Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 KBI Biopharma Main Business Overview
11.4.5 KBI Biopharma Latest Developments
11.5 Hera Biolabs
11.5.1 Hera Biolabs Company Information
11.5.2 Hera Biolabs Mammalian Cell Line Development Product Offered
11.5.3 Hera Biolabs Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Hera Biolabs Main Business Overview
11.5.5 Hera Biolabs Latest Developments
11.6 Catalent
11.6.1 Catalent Company Information
11.6.2 Catalent Mammalian Cell Line Development Product Offered
11.6.3 Catalent Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Catalent Main Business Overview
11.6.5 Catalent Latest Developments
11.7 Bionova
11.7.1 Bionova Company Information
11.7.2 Bionova Mammalian Cell Line Development Product Offered
11.7.3 Bionova Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bionova Main Business Overview
11.7.5 Bionova Latest Developments
11.8 Lonza
11.8.1 Lonza Company Information
11.8.2 Lonza Mammalian Cell Line Development Product Offered
11.8.3 Lonza Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Lonza Main Business Overview
11.8.5 Lonza Latest Developments
11.9 Creative Biolabs
11.9.1 Creative Biolabs Company Information
11.9.2 Creative Biolabs Mammalian Cell Line Development Product Offered
11.9.3 Creative Biolabs Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Creative Biolabs Main Business Overview
11.9.5 Creative Biolabs Latest Developments
11.10 Fraunhofer
11.10.1 Fraunhofer Company Information
11.10.2 Fraunhofer Mammalian Cell Line Development Product Offered
11.10.3 Fraunhofer Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Fraunhofer Main Business Overview
11.10.5 Fraunhofer Latest Developments
11.11 Cytena
11.11.1 Cytena Company Information
11.11.2 Cytena Mammalian Cell Line Development Product Offered
11.11.3 Cytena Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Cytena Main Business Overview
11.11.5 Cytena Latest Developments
11.12 GTP Bioways
11.12.1 GTP Bioways Company Information
11.12.2 GTP Bioways Mammalian Cell Line Development Product Offered
11.12.3 GTP Bioways Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 GTP Bioways Main Business Overview
11.12.5 GTP Bioways Latest Developments
11.13 Abzena
11.13.1 Abzena Company Information
11.13.2 Abzena Mammalian Cell Line Development Product Offered
11.13.3 Abzena Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Abzena Main Business Overview
11.13.5 Abzena Latest Developments
11.14 FUJIFILM Diosynth Biotechnologies
11.14.1 FUJIFILM Diosynth Biotechnologies Company Information
11.14.2 FUJIFILM Diosynth Biotechnologies Mammalian Cell Line Development Product Offered
11.14.3 FUJIFILM Diosynth Biotechnologies Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
11.14.5 FUJIFILM Diosynth Biotechnologies Latest Developments
11.15 WuXi Biologics
11.15.1 WuXi Biologics Company Information
11.15.2 WuXi Biologics Mammalian Cell Line Development Product Offered
11.15.3 WuXi Biologics Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 WuXi Biologics Main Business Overview
11.15.5 WuXi Biologics Latest Developments
11.16 Northway Biotech
11.16.1 Northway Biotech Company Information
11.16.2 Northway Biotech Mammalian Cell Line Development Product Offered
11.16.3 Northway Biotech Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Northway Biotech Main Business Overview
11.16.5 Northway Biotech Latest Developments
11.17 Sartorius
11.17.1 Sartorius Company Information
11.17.2 Sartorius Mammalian Cell Line Development Product Offered
11.17.3 Sartorius Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sartorius Main Business Overview
11.17.5 Sartorius Latest Developments
11.18 EirGenix
11.18.1 EirGenix Company Information
11.18.2 EirGenix Mammalian Cell Line Development Product Offered
11.18.3 EirGenix Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 EirGenix Main Business Overview
11.18.5 EirGenix Latest Developments
11.19 Tanvex
11.19.1 Tanvex Company Information
11.19.2 Tanvex Mammalian Cell Line Development Product Offered
11.19.3 Tanvex Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Tanvex Main Business Overview
11.19.5 Tanvex Latest Developments
11.20 Menarini Biotech
11.20.1 Menarini Biotech Company Information
11.20.2 Menarini Biotech Mammalian Cell Line Development Product Offered
11.20.3 Menarini Biotech Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Menarini Biotech Main Business Overview
11.20.5 Menarini Biotech Latest Developments
11.21 Creative Biogene
11.21.1 Creative Biogene Company Information
11.21.2 Creative Biogene Mammalian Cell Line Development Product Offered
11.21.3 Creative Biogene Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Creative Biogene Main Business Overview
11.21.5 Creative Biogene Latest Developments
11.22 Rodon Biologics
11.22.1 Rodon Biologics Company Information
11.22.2 Rodon Biologics Mammalian Cell Line Development Product Offered
11.22.3 Rodon Biologics Mammalian Cell Line Development Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 Rodon Biologics Main Business Overview
11.22.5 Rodon Biologics Latest Developments
12 Research Findings and Conclusion

List of Tables
Table 1. Mammalian Cell Line Development Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Mammalian Cell Line Development Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of CHO (Chinese Hamster Ovary) Cells
Table 4. Major Players of HEK (Human Embryonic Kidney) Cells
Table 5. Major Players of NS0 (Mouse Myeloma) Cells
Table 6. Major Players of BHK (Baby Hamster Kidney) Cells
Table 7. Major Players of Others
Table 8. Mammalian Cell Line Development Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Mammalian Cell Line Development Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Mammalian Cell Line Development Market Size Market Share by Type (2021-2026)
Table 11. Mammalian Cell Line Development Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Mammalian Cell Line Development Market Size by Application (2021-2026) & ($ millions)
Table 13. Global Mammalian Cell Line Development Market Size Market Share by Application (2021-2026)
Table 14. Global Mammalian Cell Line Development Revenue by Player (2021-2026) & ($ millions)
Table 15. Global Mammalian Cell Line Development Revenue Market Share by Player (2021-2026)
Table 16. Mammalian Cell Line Development Key Players Head office and Products Offered
Table 17. Mammalian Cell Line Development Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Mammalian Cell Line Development Market Size by Region (2021-2026) & ($ millions)
Table 21. Global Mammalian Cell Line Development Market Size Market Share by Region (2021-2026)
Table 22. Global Mammalian Cell Line Development Revenue by Country/Region (2021-2026) & ($ millions)
Table 23. Global Mammalian Cell Line Development Revenue Market Share by Country/Region (2021-2026)
Table 24. Americas Mammalian Cell Line Development Market Size by Country (2021-2026) & ($ millions)
Table 25. Americas Mammalian Cell Line Development Market Size Market Share by Country (2021-2026)
Table 26. Americas Mammalian Cell Line Development Market Size by Type (2021-2026) & ($ millions)
Table 27. Americas Mammalian Cell Line Development Market Size Market Share by Type (2021-2026)
Table 28. Americas Mammalian Cell Line Development Market Size by Application (2021-2026) & ($ millions)
Table 29. Americas Mammalian Cell Line Development Market Size Market Share by Application (2021-2026)
Table 30. APAC Mammalian Cell Line Development Market Size by Region (2021-2026) & ($ millions)
Table 31. APAC Mammalian Cell Line Development Market Size Market Share by Region (2021-2026)
Table 32. APAC Mammalian Cell Line Development Market Size by Type (2021-2026) & ($ millions)
Table 33. APAC Mammalian Cell Line Development Market Size by Application (2021-2026) & ($ millions)
Table 34. Europe Mammalian Cell Line Development Market Size by Country (2021-2026) & ($ millions)
Table 35. Europe Mammalian Cell Line Development Market Size Market Share by Country (2021-2026)
Table 36. Europe Mammalian Cell Line Development Market Size by Type (2021-2026) & ($ millions)
Table 37. Europe Mammalian Cell Line Development Market Size by Application (2021-2026) & ($ millions)
Table 38. Middle East & Africa Mammalian Cell Line Development Market Size by Region (2021-2026) & ($ millions)
Table 39. Middle East & Africa Mammalian Cell Line Development Market Size by Type (2021-2026) & ($ millions)
Table 40. Middle East & Africa Mammalian Cell Line Development Market Size by Application (2021-2026) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Mammalian Cell Line Development
Table 42. Key Market Challenges & Risks of Mammalian Cell Line Development
Table 43. Key Industry Trends of Mammalian Cell Line Development
Table 44. Global Mammalian Cell Line Development Market Size Forecast by Region (2027-2032) & ($ millions)
Table 45. Global Mammalian Cell Line Development Market Size Market Share Forecast by Region (2027-2032)
Table 46. Global Mammalian Cell Line Development Market Size Forecast by Type (2027-2032) & ($ millions)
Table 47. Global Mammalian Cell Line Development Market Size Forecast by Application (2027-2032) & ($ millions)
Table 48. Thermo Fisher Scientific Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 49. Thermo Fisher Scientific Mammalian Cell Line Development Product Offered
Table 50. Thermo Fisher Scientific Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 51. Thermo Fisher Scientific Main Business
Table 52. Thermo Fisher Scientific Latest Developments
Table 53. AGC Biologics Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 54. AGC Biologics Mammalian Cell Line Development Product Offered
Table 55. AGC Biologics Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 56. AGC Biologics Main Business
Table 57. AGC Biologics Latest Developments
Table 58. FyoniBio Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 59. FyoniBio Mammalian Cell Line Development Product Offered
Table 60. FyoniBio Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. FyoniBio Main Business
Table 62. FyoniBio Latest Developments
Table 63. KBI Biopharma Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 64. KBI Biopharma Mammalian Cell Line Development Product Offered
Table 65. KBI Biopharma Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. KBI Biopharma Main Business
Table 67. KBI Biopharma Latest Developments
Table 68. Hera Biolabs Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 69. Hera Biolabs Mammalian Cell Line Development Product Offered
Table 70. Hera Biolabs Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. Hera Biolabs Main Business
Table 72. Hera Biolabs Latest Developments
Table 73. Catalent Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 74. Catalent Mammalian Cell Line Development Product Offered
Table 75. Catalent Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Catalent Main Business
Table 77. Catalent Latest Developments
Table 78. Bionova Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 79. Bionova Mammalian Cell Line Development Product Offered
Table 80. Bionova Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. Bionova Main Business
Table 82. Bionova Latest Developments
Table 83. Lonza Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 84. Lonza Mammalian Cell Line Development Product Offered
Table 85. Lonza Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Lonza Main Business
Table 87. Lonza Latest Developments
Table 88. Creative Biolabs Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 89. Creative Biolabs Mammalian Cell Line Development Product Offered
Table 90. Creative Biolabs Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. Creative Biolabs Main Business
Table 92. Creative Biolabs Latest Developments
Table 93. Fraunhofer Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 94. Fraunhofer Mammalian Cell Line Development Product Offered
Table 95. Fraunhofer Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Fraunhofer Main Business
Table 97. Fraunhofer Latest Developments
Table 98. Cytena Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 99. Cytena Mammalian Cell Line Development Product Offered
Table 100. Cytena Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. Cytena Main Business
Table 102. Cytena Latest Developments
Table 103. GTP Bioways Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 104. GTP Bioways Mammalian Cell Line Development Product Offered
Table 105. GTP Bioways Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 106. GTP Bioways Main Business
Table 107. GTP Bioways Latest Developments
Table 108. Abzena Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 109. Abzena Mammalian Cell Line Development Product Offered
Table 110. Abzena Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 111. Abzena Main Business
Table 112. Abzena Latest Developments
Table 113. FUJIFILM Diosynth Biotechnologies Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 114. FUJIFILM Diosynth Biotechnologies Mammalian Cell Line Development Product Offered
Table 115. FUJIFILM Diosynth Biotechnologies Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 116. FUJIFILM Diosynth Biotechnologies Main Business
Table 117. FUJIFILM Diosynth Biotechnologies Latest Developments
Table 118. WuXi Biologics Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 119. WuXi Biologics Mammalian Cell Line Development Product Offered
Table 120. WuXi Biologics Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 121. WuXi Biologics Main Business
Table 122. WuXi Biologics Latest Developments
Table 123. Northway Biotech Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 124. Northway Biotech Mammalian Cell Line Development Product Offered
Table 125. Northway Biotech Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 126. Northway Biotech Main Business
Table 127. Northway Biotech Latest Developments
Table 128. Sartorius Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 129. Sartorius Mammalian Cell Line Development Product Offered
Table 130. Sartorius Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 131. Sartorius Main Business
Table 132. Sartorius Latest Developments
Table 133. EirGenix Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 134. EirGenix Mammalian Cell Line Development Product Offered
Table 135. EirGenix Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 136. EirGenix Main Business
Table 137. EirGenix Latest Developments
Table 138. Tanvex Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 139. Tanvex Mammalian Cell Line Development Product Offered
Table 140. Tanvex Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 141. Tanvex Main Business
Table 142. Tanvex Latest Developments
Table 143. Menarini Biotech Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 144. Menarini Biotech Mammalian Cell Line Development Product Offered
Table 145. Menarini Biotech Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 146. Menarini Biotech Main Business
Table 147. Menarini Biotech Latest Developments
Table 148. Creative Biogene Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 149. Creative Biogene Mammalian Cell Line Development Product Offered
Table 150. Creative Biogene Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 151. Creative Biogene Main Business
Table 152. Creative Biogene Latest Developments
Table 153. Rodon Biologics Details, Company Type, Mammalian Cell Line Development Area Served and Its Competitors
Table 154. Rodon Biologics Mammalian Cell Line Development Product Offered
Table 155. Rodon Biologics Mammalian Cell Line Development Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 156. Rodon Biologics Main Business
Table 157. Rodon Biologics Latest Developments

---